Shanghai MicroPort MedBot (Group) Co., Ltd. (2252.HK)

HKD 16.82

(2.44%)

Market Cap (In HKD)

16.81 Billion

Revenue (In HKD)

104.59 Million

Net Income (In HKD)

-1.01 Billion

Avg. Volume

13.34 Million

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
6.03-21.35
PE
-24.03
EPS
-0.7
Beta Value
1.217
ISIN
CNE100004QP1
CUSIP
-
CIK
-
Shares
999594300.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Devices
CEO
Dr. Chao He
Employee Count
-
Website
https://www.medbotsurgical.com
Ipo Date
2021-11-02
Details
Shanghai Microport Medbot (Group) Co., Ltd. engages in the research and development, design, manufacture, and sale of surgical robots in the People's Republic of China and Europe. It offers Toumai, a laparoscopic surgical robot for use in urologic, gynecologic, thoracic, and general surgeries; DFVision, a 3D electronic laparoscope, which is used in laparoscopic surgeries for abdominal, thoracic, and pelvic organs; Honghu, an orthopedic surgical robot for knee arthroplasty and hip arthroplasty; R-One, a vascular interventional surgical robot for coronary angioplasty; and iSR'obot, a Mona Lisa robotic transperineal prostate biopsy system. The company also provides spine surgical robots; trans-bronchial surgical robots for trans-bronchial diagnosis and treatment; TAVR surgical robots for heart valve replacement surgery; and automated needle targeting robotics systems for percutaneous lung biopsy and percutaneous nephrolithotomy. Shanghai Microport Medbot (Group) Co., Ltd. was founded in 2014 and is based in Shanghai, China. Shanghai Microport Medbot (Group) Co., Ltd. operates as a subsidiary of MicroPort Scientific Corporation.